Related Experiment Video
Updated: Aug 13, 2026

Purification of Ubiquitinated p53 Proteins from Mammalian Cells
Published on: March 21, 2022
Ubiquitination of p53 at multiple sites in the DNA-binding domain
Wan Mui Chan1, Man Chi Mak, Tsz Kan Fung
1Department of Biochemistry, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong.
Abstract:
The tumor suppressor p53 is negatively regulated by the ubiquitin ligase MDM2. The MDM2 recognition site is at the NH2-terminal region of p53, but the positions of the actual ubiquitination acceptor sites are less well defined. Lysine residues at the COOH-terminal region of p53 are implicated as sites for ubiquitination and other post-translational modifications. Unexpectedly, we found that substitution of the COOH-terminal lysine residues did not diminish MDM2-mediated ubiquitination. Ubiquitination was not abolished even after the entire COOH-terminal regulatory region was removed. Using a method involving in vitro proteolytic cleavage at specific sites after ubiquitination, we found that p53 was ubiquitinated at the NH2-terminal portion of the protein. The lysine residue within the transactivation domain is probably not essential for ubiquitination, as substitution with an arginine did not affect MDM2 binding or ubiquitination. In contrast, several conserved lysine residues in the DNA-binding domain are critical for p53 ubiquitination. Removal of the DNA-binding domain reduced ubiquitination and increased the stability of p53. These data provide evidence that in addition to the COOH-terminal residues, p53 may also be ubiquitinated at sites in the DNA-binding domain.
Insights
The tumor suppressor p53 is ubiquitinated by MDM2. Unexpectedly, ubiquitination occurs in the DNA-binding domain, not the COOH-terminus, impacting p53 stability.
Area of Science:
- Molecular Biology
- Cancer Research
- Protein Biochemistry
Background:
- The tumor suppressor p53 is a critical regulator of cellular responses to stress.
- p53 function is tightly controlled by negative regulators, including the ubiquitin ligase MDM2.
- MDM2 targets p53 for degradation via ubiquitination, primarily at the N-terminus.
Purpose of the Study:
- To precisely identify the ubiquitination sites of p53 mediated by MDM2.
- To investigate the role of different p53 domains in MDM2-dependent ubiquitination.
- To understand how ubiquitination affects p53 stability and function.
Main Methods:
- Site-directed mutagenesis of p53 lysine residues.
- In vitro ubiquitination assays using recombinant MDM2 and p53.
- Proteolytic cleavage mapping to identify ubiquitination sites.
- Analysis of p53 stability upon domain deletion.
Main Results:
- Substitution of COOH-terminal lysine residues did not prevent MDM2-mediated ubiquitination.
- p53 ubiquitination was found to occur in the NH2-terminal portion, specifically within the DNA-binding domain.
- Conserved lysine residues in the DNA-binding domain are critical for p53 ubiquitination.
- Deletion of the DNA-binding domain reduced ubiquitination and increased p53 stability.
Conclusions:
- p53 ubiquitination by MDM2 is not restricted to the COOH-terminal region as previously suggested.
- The DNA-binding domain of p53 contains critical ubiquitination sites essential for MDM2-mediated regulation.
- These findings reveal novel regulatory mechanisms controlling p53 stability and function.
Related Concept Videos
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Negative Regulator Molecules

